Literature DB >> 6306144

The emergence of antigenic variants is a rare event in long-term visna virus infection in vivo.

H Thormar, M R Barshatzky, K Arnesen, P B Kozlowski.   

Abstract

Six sheep persistently infected with visna virus were studied for 4 1/2 to 5 3/4 years until they became ill. Virus was isolated at intervals from peripheral blood leukocytes and cerebrospinal fluid (CSF), and at the time of sacrifice from various parts of the brain and the lungs. Both brain and lungs showed lesions typical of advanced visna/maedi. All the sheep formed antibodies in sera and CSF. Virus isolates from each sheep were tested in neutralization tests against sera and CSF collected from the same animal. In one sheep all isolates were found to be identical to the inoculated virus by this test. In each of the other sheep an antigenic variant emerged from 1 to 3 years after inoculation and remained in circulation even after the formation of autologous antibodies. In one case a variant was isolated from the lungs, whereas in all cases the virus isolated from the brain was identical to the inoculated virus. The results show that antigenic variants are rare in visna and do not seem to have a role in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306144     DOI: 10.1099/0022-1317-64-7-1427

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Role of the host immune response in selection of equine infectious anemia virus variants.

Authors:  S Carpenter; L H Evans; M Sevoian; B Chesebro
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides.

Authors:  H Thormar; C E Isaacs; H R Brown; M R Barshatzky; T Pessolano
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

3.  Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection.

Authors:  O Salinovich; S L Payne; R C Montelaro; K A Hussain; C J Issel; K L Schnorr
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

4.  Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence.

Authors:  S Kennedy-Stoskopf; O Narayan
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

Review 5.  Animal virus infections that defy vaccination: equine infectious anemia, caprine arthritis-encephalitis, maedi-visna, and feline infectious peritonitis.

Authors:  N C Pedersen
Journal:  Adv Vet Sci Comp Med       Date:  1989

6.  Naturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotype.

Authors:  R Skraban; S Matthíasdóttir; S Torsteinsdóttir; G Agnarsdóttir; B Gudmundsson; G Georgsson; R H Meloen; O S Andrésson; K A Staskus; H Thormar; V Andrésdóttir
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

7.  Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs.

Authors:  H Thormar; G Georgsson; P A Pálsson; J Balzarini; L Naesens; S Torsteinsdóttir; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Antigenic variation of neutralization-sensitive epitopes of caprine arthritis-encephalitis lentivirus during persistent arthritis.

Authors:  T C McGuire; L K Norton; K I O'Rourke; W P Cheevers
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

9.  Molecular characterization and heterogeneity of feline immunodeficiency virus isolates.

Authors:  N Maki; T Miyazawa; M Fukasawa; A Hasegawa; M Hayami; K Miki; T Mikami
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.

Authors:  D P Burns; C Collignon; R C Desrosiers
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.